Myriad Genetics, Inc.

NASDAQ:MYGN

Medical - Diagnostics & Research

Healthcare
$5.53 +3.20%

+$0.14 today

Market cap
$530.45M
Beta
1.64
P/E (TTM)
-1.1
EPS (TTM)
-$4.27
52W Low $3.53High $8.59

Volume 1.26M

Average 1.81M

MYGN Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

Myriad Genetics, Inc.NASDAQ: MYGN

Revenue · Q1 FY2026 · quarter ended Mar 2026

Revenue growth accelerates

Q1 FY2026 revenue of $200.4M rose 2.3% year over year, ahead of the -0.3% change in trailing-twelve-month revenue. Sequentially, it fell 4.5% from the prior quarter. Over 3 fiscal years it compounded at +6.7% a year.

Context

  • Revenue increased in 2 of the last 3 fiscal years.

What to watch

Whether revenue reaches the consensus estimate from 5 analysts of $785.28M (-4.8%) for the fiscal year ending Dec 2026, a slowdown from the -1.6% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$200.4M-4.5% QoQ
Last fiscal yearDec 2025
$824.5M-1.6% YoY
LTMMar 2026
$829M-0.3% YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+2.3%-3.3%-5.6 pp
1 year-1.6%-4.8%-3.2 pp
3-year CAGR+6.7%-4.6%-11.3 pp
5-year CAGR+0.3%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

USD · from the income statement

Latest · FY2025
824.5M USD
Year-over-year change
-1.6%
4-year CAGR
+4.5%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How MYGN compares with its peers on the latest reported figures

  • MYGN's LTM Mar 2026 revenue of $829M is the 4th highest of the 10 companies compared; the peer median is $561.9M.
  • Its year-over-year change of -0.3% is the 8th highest of 10, against a peer median of +11.2%.
  • Over three fiscal years its annual growth of +6.7% compares with a peer median of +20.4%.
MYGN Competitors Peer median
Revenue for MYGN and competitors
Company Period LTM YoY 3-year CAGR
NTRANatera, Inc.LTM Jun 2026$2.71B +37.8%+41.1%
QGENQiagen N.V.LTM Jun 2026$2.1B +3.0%-0.8%
GHGuardant Health, Inc.LTM Sep 2026$1.28B +41.7%+29.8%
MYGNMyriad Genetics, Inc.LTM Mar 2026$829M -0.3%+6.7%
NEONeoGenomics, Inc.LTM Jun 2026$766.3M +11.2%+12.6%
VCYTVeracyte, Inc.LTM Jun 2026$561.9M +17.3%+20.4%
BLLNBillionToOne, Inc.LTM Jun 2026$397.41M +90.1%—
FLGTFulgent Genetics, Inc.LTM Mar 2026$320.35M +9.5%-19.5%
PSNLPersonalis, Inc.LTM Mar 2026$64.52M -24.7%—
IMDXInsight Molecular Diagnostics Inc.LTM Mar 2026$1.95M -49.3%+61.8%
Peer median (excluding MYGN) $561.9M+11.2%+20.4%

Competitors are the stored peer set for MYGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue690.6M678.4M753.2M837.6M824.5M
Cost of Revenue197.6M202M236.2M252.2M247.9M
Gross Profit493M476.4M517M585.4M576.6M
Gross Margin71.4%70.2%68.6%69.9%69.9%
Research & Development81.9M85.4M88.7M113.4M106.8M
Selling, General & Admin537.8M514.7M572.9M560M537.6M
Operating Expenses683.5M617M774.4M708.9M644.4M
Depreciation & Amortization62.8M52.7M61.9M61.2M53.7M
EBITDA12.3M(84.7M)(197.4M)(59.5M)(330.9M)
EBITDA Margin1.8%-12.5%-26.2%-7.1%-40.1%
Operating Income(190.5M)(140.6M)(257.4M)(123.5M)(67.8M)
Operating Margin-27.6%-20.7%-34.2%-14.7%-8.2%
Interest Income700K2.6M2.5M1.7M1.8M
Interest Expense6.6M3.2M2.9M2.8M10.5M
Other Income / Expenses133.4M(16.9M)(4.8M)(35.5M)(327.3M)
Income Before Tax(57.1M)(140.6M)(262.2M)(123.5M)(395.1M)
Pre-Tax Margin-8.3%-20.7%-34.8%-14.7%-47.9%
Income Tax Expense(29.9M)(28.6M)1.1M3.8M(29.2M)
Net Income(27.2M)(112M)(263.3M)(127.3M)(365.9M)
Net Margin-3.9%-16.5%-35.0%-15.2%-44.4%
EPS (Basic)(0.35)(1.39)(3.18)(1.41)(3.96)
EPS (Diluted)(0.35)(1.39)(3.18)(1.41)(3.96)
Weighted Avg Shares77.71M80.58M82.8M90.6M93.3M
Weighted Avg Shares (Diluted)78M80.6M82.8M90.6M93.3M

Myriad Genetics, Inc.

NASDAQ:MYGN

Intrinsic Alpha fair value

Locked

Current Price

$5.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.